2020_Milestones_About Us__MobiDrop (Zhejiang) Co., Ltd.

About Us MobiDrop is a microfluidics-enabled innovator in life sciences and precision medicine .

MobiDrop is the first multi-platform molecular diagnostic company in China. Driven by the third-generation microfluidic technologies, MobiDrop is committed to empowering revolutionary advances in life sciences and precision medicine.

Led by a world-class executive team and chief scientist Dr. David Weitz from Harvard University, MobiDrop develops advanced instruments, comprehensive assays, and easy-to-use software for ddPCR and single-cell multiomic platforms. The company is headquartered at Jiaxing, China and has the Center for Global Innovation and Business Development at Boston, U.S.

Headquartered in Jiaxing, Zhejiang, China, Mobidrop has more than 4,000 square meters of office, laboratory and factory space, including P2 cell culture labs, PCR amplification labs, and an 800 square-meter GMP manufacturing plant. Since its establishment, the company has owned more than 30 independent intellectual property rights, including 15 exclusive patents granted by Harvard University.

Jiaxing, China: The Global Headquarter for R&D and Production

Headquartered in Jiaxing, Zhejiang, China, Mobidrop has more than 4,000 square meters of office, laboratory and factory space, including P2 cell culture labs, PCR amplification labs, and an 800 square-meter GMP manufacturing plant. Since its establishment, the company has owned more than 30 independent intellectual property rights, including 15 exclusive patents granted by Harvard University.
The Center for Global Innovation and Business Development is located at Cambridge, Massachusetts, USA. The mission of the center is to closely collaborate with Harvard University in research and to expand the company's global collaborations and business.

Boston, USA: The Center for Global Innovation and Business Development

The Center for Global Innovation and Business Development is located at Cambridge, Massachusetts, USA. The mission of the center is to closely collaborate with Harvard University in research and to expand the company's global collaborations and business.

Executive Team

MobiDrop is led by world-class scientists, engineers, and executives.

Dr. Hao Pei, Founder & CEO

PhD, Harvard University
With a strong expertise in microfluidics, IVD products, and business management
Dr. Wenshan Zheng, founder & CTO

PhD, Harvard University
With a strong expertise in microfluidics-enabled single cell multiomics
Dr. Han Liu Founder & COO

PhD, Harvard University
Experienced entrepreneur with strong scientific and business background, 12 years of healthcare industry experience spanning various functions in founding/growing companies. EM at McKinsey&Company, product director in Clarify health silicon valley.
David Weitz

Chief Scientist
A world-class pioneer in microfluidics, tenured professor at Harvard University, member of the National Academy of Sciences, the National Academy of Engineering, and the American Association of Arts and Sciences, and foreign member of the Chinese Academy of Engineering
Mike Kopczynski

Advisory Board Member
Senior Vice President of Life Technologies

Milestones

2021

• January | Signed strategic cooperation agreements with leading single-cell sequencing service providers in China
• February | Established a joint R&D center for single-cell sequencing with Tongji University
• April | Obtained the first medical device certificate from the National Medical Products Administration (NMPA)
• May | Launched the production base at Wuzhen
2020

• January | Signed R&D collaboration agreements with the Shanghai Ninth People's Hospital and the Shanghai Tsinghua International Innovation Center
• May | Signed a R&D collaboration framework with the Zhejiang Provincial Center for Disease Control and Prevention
• August | Signed a strategic cooperation agreement with the Wuzhen government and established MobiDrop (Zhejiang) Co., Ltd.
• October | Received tens of millions of pre-A funding
• November | Earned the top reward from the 2020 Tongxiang Leading Elite Program with the project of “Microfluidic Biological Detection Chips”
• December | Released the first-generation all-in-one digital PCR system
2019

• March | Developed innovative all-in-one digital RCR microfluidic chip "MobiChip"
• October | Developed MobiDrop single-cell sequencing prototype protocol
2018

• May | Founded at Harvard University
• August | Esteblished MobiDrop (Shanghai) Co., Ltd. officially
• September | Received seed funding